RegenLab

Regen Lab SA, founded in 2003, designs and manufactures medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures. The company has achieved milestones including the first approval of RegenKit in bone graft in 2010, a new laboratory in Lausanne in 2013, and the approval and launch of Cellular Matrix in Europe in 2014 and 2015 respectively.

Regen Lab SA was founded in 2003. In 2010, RegenKit received its first approval in bone graft. In 2013, a new state-of-the-art laboratory was established in Lausanne. In 2014, Cellular Matrix received its first approval, and in 2015, Cellular Matrix was launched in Europe.

• RegenPRP™

  A medical treatment that uses platelet-rich plasma from the patient's own blood to enhance tissue regeneration.

• RegenPRP™ - HA

  A combination treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

• RegenPRP™ - ATS

  An advanced approach using autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

• RegenExtracell®

  An innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

• RegenWound

  A fully autologous solution prepared from the patient's own blood, with the objective of providing a standardised and reproducible approach for clinical use.

1. 1Regen Lab | Tissue Engineering & Regenerative Medicineregenlab.com